![]() ![]() Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. ![]() Ventana is a wholly owned member of the Roche Group. In addition, the Company offers premier workflow solutions designed to improve laboratory efficiency, providing safeguards to enhance the quality of healthcare. Ventana drug discovery systems are used to accelerate the discovery of new drug targets and evaluate the safety of new drug compounds. The Company's clinical systems are important tools used in the diagnosis and treatment of cancer and infectious diseases. Ventana develops, manufactures, and markets instrument/reagent systems that automate tissue preparation and slide staining in clinical histology and drug discovery laboratories worldwide. Ībout Ventana Medical Systems, Inc./ Roche Tissue Diagnostics BioImagene's innovative product line includes a unique image viewing input device called the iSlide, and a high-performance pathology workstation called Crescendo. The company's total digital pathology solution is comprised of the Virtuoso digital pathology application software, iScan family of automated digital slide scanners, and a rich menu of Companion Algorithms. With BioImagene's current and future products we will be able to deliver an end-to-end solution from automated staining to comprehensive patient reports."īioImagene is a leading provider of innovative and scalable digital pathology solutions. "Our VIAS Image Analysis System was the first entry into the digital pathology market and is now the leading system for automated image analysis in breast cancer. "Through this acquisition, Ventana is uniquely positioned to improve laboratory efficiency and help pathologists improve patient care," said Hany Massarany, President of Ventana Medical Systems, Inc. In addition, their products improve workflow efficiency in image archiving and retrieval, remote case review, and turnaround time. They also provide the software to view, analyze and manage tissue images using a computer, taking pathology beyond traditional microscope applications. In turn, BioImagene brings to Ventana additional capabilities for scanning and analysing tissue that are not possible in the glass-slide world."īioImagene's products create high-resolution, whole-slide digital images from glass microscope slides. "Ventana is already a leader in image analysis for breast cancer applications and has a wide range of market-leading diagnostics products used in hospitals and laboratories worldwide. "With its leadership position in pathology and its global reach, Ventana is the ideal partner for BioImagene," commented Ajit Singh, CEO of BioImagene, Inc. BioImagene products will complement and strengthen our current offering in image analysis and information management." "The increasing complexity of new tests and technologies creates tremendous need for more sophisticated tools for tissue analysis and diagnosis. "As part of the personalised healthcare approach, pathologists are increasingly involved in generating information with high impact on treatment decisions," said Daniel O'Day, COO Roche Diagnostics. Digital pathology is a suite of dynamic, image-based technologies that enable image capture, information management, image analysis and virtual sharing of patients' tissue samples on glass slides. The transaction is subject to customary closing conditions and is expected to close in the coming weeks.īioImagene is an innovative leader in the field of digital pathology workflow and analysis. The purchase price is approximately 100 million US dollars on a debt-free basis. Roche announced recently that it has signed an agreement under which Ventana Medical Systems Inc., a member of the Roche Group, will acquire 100 percent of BioImagene, Inc., a privately held company based in Sunnyvale, California. Acquisition further strengthens Roche's global leadership in tissue-based cancer diagnostics and research ![]()
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |